Lung carcinoma is the leading cause of cancer mortality worldwide. Currently, cancer staging and prognosis are determined using histopathology and clinical factors such as lymph node status. However, even the earliest stage of non-small cell lung carcinoma has a widely varying prognosis.

In this review, the evolution and refinement of molecular predictors of prognosis in lung carcinoma are described.